Chinese regulators have granted Boston Scientific approval to market its Alair Bronchial Thermoplasty device in that country. The device, which the company acquired through its $193.5 million purchase of Asthmatx in 2010, is designed to treat severe asthma patients who have failed to respond to long-acting beta-agonists or inhaled corticosteroids.
Boston Scientific gains approval for asthma device in China
SmartBrief Job Listings for Health Care
|Senior Research Analyst||
America's Health Insurance Plans (AHIP)
|Manager, Regulatory Affairs||
|Washington DC, DC|
|Senior Counsel - FDA Regulatory Affairs||
|Director, Quality Assurance||
|Provider Relations Manager||
Breakthrough Behavioral, Inc.
|Redwood City, CA|